Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEVOsq
2023-510320-71-00Phase 2Completed
- Sponsor
- Unicancer
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and vorinostat in head and neck squamous cell carcinoma (HNSCC), cervical squamous cell carcinoma (CSCC), squamous cell carcinoma of the anus and 3 more, sponsored by Unicancer. Primary endpoint: Objective response rate (ORR) by investigator (RECIST v1.1). Started Oct 2020; status: completed.
02
Drugs
pembrolizumabvorinostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)cervical squamous cell carcinoma (CSCC)squamous cell carcinoma of the anusvulvar squamous cell carcinoma (VSCC)vaginal squamous cell carcinoma (SCCV)
Beyond the preview
Go deeper on 2023-510320-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510320-71-00.